Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases.
about
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptorBiomarker development in MET-targeted therapyEvolutionary conservation and expression of human RNA-binding proteins and their role in human genetic diseaseMET: a critical player in tumorigenesis and therapeutic targetReceptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells.Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor).Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processingTwo rearranged MET alleles in MNNG-HOS cells reveal the orientation of MET on chromosome 7 to other markers tightly linked to the cystic fibrosis locusHigh concentrations of HGF inhibit skeletal muscle satellite cell proliferation in vitro by inducing expression of myostatin: a possible mechanism for reestablishing satellite cell quiescence in vivo.A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells.Signaling mechanisms that suppress the cytostatic actions of rapamycinInvasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma.Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors.In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell deathTargeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cellsActivation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.Constitutive activation of the RON gene promotes invasive growth but not transformation.The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylationTumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factorC-terminal truncated forms of Met, the hepatocyte growth factor receptortpr-met oncogene product induces maturation-producing factor activation in Xenopus oocytes.Product of the oncogene-activating gene Tpr is a phosphorylated protein of the nuclear pore complex.A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.Regulation of the MET oncogene: molecular mechanisms.The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.Increased engraftment of hepatic progenitors after activation of the hepatocyte growth factor signaling pathway by protein transduction.Uncoupling ligand-dependent and -independent mechanisms for mitogen-activated protein kinase activation by the murine Ron receptor tyrosine kinase.Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction.Oncogenes and anti-oncogenes in human epithelial thyroid tumors.Hepatocyte growth factor and Madin-Darby canine kidney cells: in vitro models of epithelial cell movement and morphogenesis.Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation.The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor.Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase.Cooperative roles of hepatocyte growth factor and plasminogen activator in tubular morphogenesis by human microvascular endothelial cells.Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.
P2860
Q24564783-F83F3FC2-E42A-4BCB-A806-AF6C35E4F8CEQ26751332-DB07AD30-3107-45D1-822B-CA4C4785D145Q26991754-2012719A-B214-4B1F-BDFB-A98D66E60731Q27008925-EF10731C-219E-4192-AB72-0EE5172D9FEEQ30791975-0BB8C370-89E5-4438-B3E0-8D3A1A964693Q30929211-973FC848-2672-48ED-BE80-7C7141156014Q33238614-8A1623F9-EDAE-4C33-B039-49954BFC0014Q33263389-317A21C6-4DE4-4BC0-A4D5-9FBF34F0DDD1Q33567327-BF036DBB-4CCF-494C-BBA1-1510F9F84E8FQ33727656-09934479-76B8-4DB4-8C6E-C1F85FF2DF8DQ34185858-4D6AB9EA-3906-442C-87F9-201E688FC646Q34358610-A5A5D7E3-A7C5-4FD3-80B0-7C142904A23AQ34482678-9CE20B94-0BC1-4EF0-BDBA-82830E8AA882Q35187701-08528CA8-9976-4487-A093-5DB178CE8C0BQ35277738-F5930E6F-CF63-40D9-9CB4-32675931B8B2Q35426283-08AF16FB-9BA9-4445-9B6D-EAF6CA3A982AQ35782214-720D4557-611F-4CF1-BF3A-BB054A898AD6Q35832669-9F2A7CD7-D832-4836-AA7C-BB4524A6820CQ35872516-5831E7CF-FB54-4F74-8899-92E1CA4E5203Q36234151-DD162751-D940-4417-9E1C-BB2B686340F4Q36326357-31650249-764A-47C3-A0C6-FF81B66A7C96Q36564393-7328E5BE-CE86-4F97-B050-34EB74D4CF07Q36687206-47A811C5-06BC-4740-8171-29E06630BB87Q36705281-33B27F12-28A9-48DF-A8A0-917D83B5F067Q36743037-B4CA0598-06CC-4B41-82E1-A9B12F77DF46Q36743308-76EDCC54-F96C-4647-B9CC-631E498EDCB8Q36809832-1CB1CE0D-1993-4ED6-B811-AB2E93574820Q37329953-36179B4B-3786-4AD7-B357-B9504DB014DBQ38746401-AE36E9BF-8E38-4DA6-B7A3-132A4E006F29Q39594896-9F360E61-DF8B-43EB-A1CA-C0B4962D29F4Q39834676-CDE4F8A8-EE10-4C50-A6B8-3D5643FD8D16Q40384638-0BA1ACB0-317D-4CAC-9DF6-3620EF2FE0FBQ40560399-C5BACD6C-C1B2-45F5-8D0D-D4D7520BE47DQ40698212-8E48210A-B6AF-4F09-BB0E-73B3EBC27F2AQ40987305-CBB83C73-B318-4D80-8241-ACC2162883A1Q41007034-9630DCA1-9159-4311-9CDF-79C3A0B3EFAEQ41155456-4845AC6D-316C-40CD-BF03-BDD3937671CCQ41168656-5324E841-FCBA-441E-A123-CB42122F21C1Q41507260-DDC513FC-7A36-4E1C-B09F-A31AC7F795E2Q41596252-770A5CFE-23EB-40E2-9521-43DA3576A742
P2860
Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1988
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@en
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@nl
type
label
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@en
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@nl
prefLabel
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@en
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@nl
P2093
P2860
P356
P1476
Characterization of the TPR-ME ...... p140 protein-tyrosine kinases.
@en
P2093
G F Vande Woude
M Gonzatti-Haces
S Oroszlan
T Copeland
P2860
P356
10.1073/PNAS.85.1.21
P407
P577
1988-01-01T00:00:00Z